HomeFilePharmacology

Pharmacology

DAPT Substudy: Score to Personalize Optimal Dual Antiaggregation Therapy Duration

Original Title: Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the...

SPRINT: lower blood pressure targets for many hypertensive

Original Title: A randomized trial of intensive versus standard blood-pressure control. Presenter: Wright JR Jr. A systolic blood-pressure target...

PEGASUS-TIMI 54 Subanalysis: Discontinuation of Ticagrelor Mostly Due to Dyspnea or Bleeding

Original Title: Long-term tolerability of ticagrelor for secondary prevention: insights from PEGASUS-TIMI 54 trial. Presenter: Bonaca MP. The higher...

JUPITER Subanalysis: Reduction of LDL Determines Clinical Impact of Rosuvastatin Therapy

Original Title: Cholesterol treatment targets and clinical outcomes: a JUPITER trial update. Presenter: Paul Ridker. The lower the LDL...

Meta-analysis of prolonged DAT after DES

Extending the antiaggregation therapy over a year reduces adverse events in patients with a history of AMI,...

Risks and benefits of extending dual antiplatelet therapy in patients with and without MI

Original title: Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without...

Duration of double antiaggregation therapy in patients with oral anticoagulation

Original title: Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent ImplantationThe ISAR-TRIPLE Trial. Reference: Katrin A....

Long term ticagrelor after an acute myocardial infarction

Original title: Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. PEGASUS-TIMI 54. Referencia: Marc P. Bonaca et al....